Corvus Pharmaceuticals, Inc.
Clinical-stage biopharma developing therapies for immune diseases and cancer.
CRVS | US
Overview
Corporate Details
- ISIN(s):
- US2210151005
- LEI:
- Country:
- United States of America
- Address:
- 863 MITTEN ROAD, 94010 BURLINGAME
- Website:
- https://www.corvuspharma.com/
- Sector:
- Manufacturing
Description
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for immune diseases and cancer. The company focuses on pioneering ITK (Interleukin-2-inducible T-cell kinase) inhibition as a new approach to modulate and control signaling pathways within the immune system. Its lead product candidate, soquelitinib, is a first-in-class, oral therapy that selectively inhibits ITK and is being developed for the treatment of T-cell lymphomas and other immune-related conditions. Corvus is advancing a pipeline of clinical-stage programs with differentiated mechanisms of action designed to precisely target critical immune pathways.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Corvus Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Corvus Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Corvus Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
